E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ocular hypertension or open angle glaucoma |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare mean reduction in diurnal IOP between each of the two groups receiving BVT.28949 (2 mg/mL, 7 mg/mL) and the placebo group after 4 weeks of treatment. |
|
E.2.2 | Secondary objectives of the trial |
- To compare mean reduction in diurnal IOP between each of the two groups receiving BVT.28949 (2 mg/mL, 7 mg/mL) and the placebo group after 2 weeks of treatment. - To compare the differences in mean IOP reducing effect for the two groups receiving BVT.28949 (2 mg/mL, 7 mg/mL) and the placebo group for each time point during the 8-hour IOP assessment (i.e., at 8:00, 10:00, 12:00, 14:00, and 16:00) after 2 and 4 weeks of treatment, respectively, and for the 8:00 assessments also after 1 and 3 weeks of treatment. - To assess the ocular safety and tolerability of BVT.28949 by assessment of ocular adverse events and best corrected visual acuity and refraction. - To monitor the general safety and tolerability of BVT.28949 by assessment of adverse events, safety laboratory analyses, vital signs including pulse and blood pressure, and 12-lead ECG.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients, ≥18 years of age, diagnosed with ocular hypertension or open angle glaucoma (OAG), either untreated or controlled on mono-therapy. 2. Treatment-naïve patients with a mean morning IOP of ≥21 mmHg to ≤30 mmHg in each separate eye at screening2 (Visit 2) and a diurnal IOP at randomization (Visit 3) of ≥21 mmHg to ≤ 30 mmHg in both eyes at randomization (Visit 3), or patients on mono-therapy for treatment of OH or OAG with a mean morning IOP of ≥17 mmHg to ≤30 mmHg in each separate eye at screening (Visit 1) and a diurnal IOP of ≥21 mmHg to ≤30 mmHg in both eyes after wash-out (at randomization, Visit 3). 3. Best corrected visual acuity score of 20/80 by Snellen (0.6 logMAR) acuity measurement, or better, in both eyes. 4. Signed informed consent to participate in this study.
|
|
E.4 | Principal exclusion criteria |
1. Previous ocular surgery, including laser procedures, affecting the trabecular meshwork or cornea without time limit, as well as other kinds of ocular surgery, including laser procedures, if performed less than 6 months before randomization. 2. Anticipated need to initiate or modify medication (systemic or topical) that is known to affect IOP (e.g. beta-adrenergic antagonists, alfa-adrenergic agonists, calcium channel blockers, ACE inhibitors and angiotensin II receptor antagonists) during the study period. Dosage of such medication should not have been altered within 4 weeks prior to randomization. 3. Any condition in either eye that may prevent reliable applanation tonometry. 4. Anterior chamber angle less than grade 2 according to Shaffer classification as measured by gonioscopy. 5. Patients with advanced visual field defect in either eye. For Humphery perimeter MD greater than -12.0 dB and Octopus perimeter MD score greater than +9.5. Or severe central visual field loss defined as a sensitivity of less than or equal to 10 dB in at least two of the four visual field test points closest to the point of fixation. 6. Patients with a cup/disc ratio greater than 0.8 in either eye on the horizontal or vertical measurement. 7. Use of contact lenses within 3 weeks prior to randomization and during the study. 8. Continuous use of ocular medication during the study period, other than the study medication. 9. History or presence of other abnormal ocular condition(s) or symptom(s) preventing the patient from entering the study, as judged by the investigator (e.g. uveitis, ocular inflammations/infections, or severe dry eye). 10. Myopia of -6 diopters or more. 11. Diabetes type I. 12. History or presence of clinically significant medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, as judged by the investigator. 13. Females of childbearing potential. Note: All females must be surgically sterilized or postmenopausal (amenorrhea for at least 12 months). 14. Suspected or known drug or alcohol abuse within the past 12 months. 15. Enrolment in another concurrent investigational study or intake of an investigational drug within 12 weeks before randomization. 16. Inability to comply with or tolerate study procedures, including ocular examinations, as judged by the investigator. 17. Inability to understand or cooperate with given information, as judged by the investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mean change of diurnal IOP of 2 mmHg |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |